{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.7","upperLimit":"93.9","value":"90.0"},{"groupId":"OG001","lowerLimit":"92.1","upperLimit":"97.2","value":"95.3"}]}],"title":"3 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.6","upperLimit":"85.3","value":"79.4"},{"groupId":"OG001","lowerLimit":"81.8","upperLimit":"89.9","value":"86.4"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.6","upperLimit":"70.5","value":"62.7"},{"groupId":"OG001","lowerLimit":"72.1","upperLimit":"82.0","value":"77.5"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.5","upperLimit":"55.4","value":"45.1"},{"groupId":"OG001","lowerLimit":"62.2","upperLimit":"74.0","value":"68.5"}]}],"title":"18 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"description":"Time to progression was defined as the time (in months) from randomization to documented disease progression. This outcome reports TTP as the percentage of participants who were event free (that is, they had not had disease progression) at the specified time frames. Independent Review Committee assessment for this outcome measure was not planned after the primary analysis.\n\n95% CIs for event-free rates were estimated using the method by Kalbfleisch and Prentice (1980) with log-log transformation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib was administered intravenously (IV) at 20 mg/m\\^2 in Cycle 1: days 1 and 2; at 56 mg/m\\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.\n\nDexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles.","id":"OG000","title":"Kd - Carfilzomib and Dexamethasone"},{"description":"Carfilzomib was administered intravenously (IV) at 20 mg/m\\^2 in Cycle 1: days 1 and 2; at 56 mg/m\\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.\n\nDexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.\n\nDaratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg dosage was continued on Cycles 7+: day 1 only.","id":"OG001","title":"KdD - Carfilzomib, Dexamethasone and Daratumumab"}],"paramType":"NUMBER","populationDescription":"Intent to Treat Population","reportingStatus":"POSTED","timeFrame":"Randomization to Months 3, 6, 12, and 18","title":"Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (PA DCO Only)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}